Bromodomain Testis Specific Protein Drug Development Research Report 2021 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Bromodomain Testis Specific Protein - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) pipeline Target constitutes close to 5 molecules.

The latest report Bromodomain Testis Specific Protein - Drugs In Development, 2021, outlays comprehensive information on the Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Bromodomain testis-specific protein is a protein encoded by the BRDT gene. It plays a role in meiotic and post-meiotic cells by binding to acetylated histones at the promoter of specific meiotic and post-meiotic genes, facilitating their activation at the appropriate time. It binds to hyperacetylated histones and participates in their general removal from DNA. The molecules developed by companies in Phase III, Phase II and Phase I stages are 1, 1 and 3 respectively.

Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Solid Tumor, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Ovarian Cancer, Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Follicular Lymphoma, Lung Cancer, Lymphoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, Myeloproliferative Disorders, Non-Small Cell Lung Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Mediastinal B-Cell Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Unspecified B-Cell Lymphomas.

Furthermore, this report also reviews key players involved in Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

• The report provides a snapshot of the global therapeutic landscape for Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT)
• The report reviews Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics and enlists all their major and minor projects
• The report assesses Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics

Key Topics Covered:

Introduction

• Report Coverage

Overview

Therapeutics Development

• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies

Therapeutics Assessment

• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Companies Involved in Therapeutics Development

• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co
• Constellation Pharmaceuticals Inc
• Ningbo Wenda Pharmaceutical Technology Co Ltd
• Zenith Epigenetics Ltd

Drug Profiles

• BI-894999 - Drug Profile
• CC-95775 - Drug Profile
• NHWD-870 - Drug Profile
• pelabresib - Drug Profile
• ZEN-3694 - Drug Profile

Dormant Products

Discontinued Products

Product Development Milestones

Featured News & Press Releases

• Jun 11, 2021: Constellation Pharmaceuticals provides an update from the ongoing MANIFEST study of Pelabresib
• Jun 11, 2021: Constellation Pharmaceuticals provides an update from the Ongoing MANIFEST study of Pelabresib
• Mar 15, 2021: Zenith Epigenetics announces dosing of first mCRPC patient with a combination of ZEN-3694 + Merck's immune check point inhibitor KEYTRUDA
• Jan 07, 2021: Constellation Pharmaceuticals appoints Brendan Delaney as Chief Commercial Officer
• Dec 06, 2020: Constellation Pharmaceuticals provides update of MANIFEST study for CPI-0610 at ASH Meeting
• Nov 23, 2020: Constellation Pharmaceuticals to host analyst / investor event to discuss update of MANIFEST clinical trial for CPI-0610 presented at ASH Meeting
• Jul 29, 2020: Zenith Epigenetics advances ZEN-3694 in multiple cancer programs
• Jul 29, 2020: Researchers optimistic after dose-determining trial of compound against metastatic castration-resistant prostate cancer
• Jun 12, 2020: Constellation Pharmaceuticals provides updates of MANIFEST study for CPI-0610 and EZH2 Franchise
• May 28, 2020: Constellation Pharmaceuticals to host analyst/investor event to discuss update of MANIFEST clinical trial for CPI-0610
• May 28, 2020: Constellation Pharmaceuticals to host analyst / investor event to discuss update of MANIFEST clinical trial for CPI-0610
• May 14, 2020: Constellation Pharmaceuticals provides update of preliminary data for CPI-0610 in three EHA Abstracts
• Apr 15, 2020: New cancer drug shrinks tumors, reduces side effects, in animal studies
• Jan 07, 2020: Zenith Epigenetics receives US$5 million milestone payment from Newsoara

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5onzwv

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900